TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

aTyr Pharma, Inc. (ATYR) Failed Drug Trial Spurs Securities Lawsuit; Class Period Significantly Enlarged -- Hagens Berman

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Hagens Berman
aTyr Pharma, Inc. (ATYR) Failed Drug Trial Spurs Securities Lawsuit; Class Period Significantly Enlarged -- Hagens Berman

aTyr Pharma faced a significant securities lawsuit after its Phase 3 drug trial for Efzofitimod failed to meet primary endpoints, causing an 83.2% stock price drop and allegations of misleading investors about the drug's efficacy.

Insights
ATYR   negative

Stock price collapsed by 83.2% after failed drug trial, facing securities lawsuit alleging misleading statements about drug efficacy, and potential regulatory challenges